Regeneron and Fujifilm Diosynth Biotechnologies Announce Groundbreaking $3 Billion Deal

In a landmark agreement, Regeneron Pharmaceuticals Inc. has partnered with Fujifilm Diosynth Biotechnologies to enhance the production and supply of Regeneron's commercial biologic medicines. This collaboration, centered at Fujifilm's North Carolina campus, represents a total investment of over $3 billion, spanning technology transfer and a decade-long commitment.

A Strategic Move to Meet High Standards and Expand Capacity

Daniel Van Plew, Regeneron's Executive Vice President, emphasized the strategic importance of this partnership. "Our alliance with Fujifilm is a testament to our shared commitment to excellence and innovation in biologic medicine production," Van Plew stated. The companies are already mobilizing to operationalize Fujifilm's Holly Springs facility, ensuring it meets Regeneron's stringent quality benchmarks.

Regeneron's Ambitious $7 Billion Investment in US Manufacturing Infrastructure

Beyond this partnership, Regeneron is channeling more than $7 billion into expanding its production and infrastructure footprint across New York and North Carolina. This investment underscores Regeneron's dedication to bolstering the US's capacity in biologic medicine manufacturing, ensuring supply chain resilience and innovation leadership.